Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10911101 | Lung Cancer | 2014 | 4 Pages |
Abstract
On the basis of the evidence currently available, it may be concluded that VAMLA and TEMLA have no contemporarily use in the routine mediastinal staging of lung cancer. This is because of their invasiveness and - at least for TEMLA - high risk of complications and mortality, which renders it unacceptable as a diagnostic procedure, and also due to the development of equally accurate, but far less invasive techniques, i.e. EBUS-NA and EUS-NA.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
JarosÅaw KużdżaÅ, Janusz Warmus, Zbigniew Grochowski,